Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; TARGET Investigators. Tauchi T, et al. Among authors: murayama t. Leuk Res. 2011 May;35(5):585-90. doi: 10.1016/j.leukres.2010.10.027. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145591
Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.
Nishida T, Murayama T, Hirai H, Okamoto S, Sao H, Hara M, Kanamori H, Atsuta Y, Matsuo K, Morishima Y, Kodera Y. Nishida T, et al. Among authors: murayama t. Int J Hematol. 2009 Jan;89(1):98-105. doi: 10.1007/s12185-008-0219-8. Epub 2008 Dec 4. Int J Hematol. 2009. PMID: 19052693 Clinical Trial.
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.
Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T. Sakura T, et al. Among authors: murayama t. Leukemia. 2018 Mar;32(3):626-632. doi: 10.1038/leu.2017.283. Epub 2017 Sep 15. Leukemia. 2018. PMID: 28914260 Clinical Trial.
Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation.
Takami A, Shimadoi S, Sugimori C, Takemoto K, Shibayama M, Yoshida T, Murayama T, Nagai K, Miyamura K, Asakura H, Nakao S. Takami A, et al. Among authors: murayama t. Int J Hematol. 2006 Aug;84(2):170-3. doi: 10.1532/IJH97.06066. Int J Hematol. 2006. PMID: 16926141
Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.
Shiratori S, Sugita J, Ota S, Kasahara S, Ishikawa J, Tachibana T, Hayashi Y, Yoshimoto G, Eto T, Iwasaki H, Harada M, Matsuo K, Teshima T; Japan Study Group for Cell Therapy and Transplantation (JSCT). Shiratori S, et al. Bone Marrow Transplant. 2021 Jan;56(1):129-136. doi: 10.1038/s41409-020-0985-3. Epub 2020 Jul 5. Bone Marrow Transplant. 2021. PMID: 32624582 Clinical Trial.
Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Mukae J, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y. Kako S, et al. Among authors: murayama t. Int J Hematol. 2021 Nov;114(5):608-619. doi: 10.1007/s12185-021-03198-4. Epub 2021 Jul 30. Int J Hematol. 2021. PMID: 34328634
1,146 results